Compare · ACGN vs ARGX
ACGN vs ARGX
Side-by-side comparison of Aceragen Inc. (ACGN) and argenx SE (ARGX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ACGN and ARGX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX carries a market cap of $16.17B.
- ARGX has hit the wire 2 times in the past 4 weeks while ACGN has been quiet.
- ARGX has more recent analyst coverage (25 ratings vs 0 for ACGN).
- Company
- Aceragen Inc.
- argenx SE
- Price
- $0.38-15.18%
- $780.08-1.00%
- Market cap
- -
- $16.17B
- 1M return
- -
- +11.90%
- 1Y return
- -
- +25.72%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 0
- 2
- Recent ratings
- 0
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ACGN
- 12 Health Care Stocks Moving In Wednesday's After-Market Session
- Axogen shares are trading lower after the company reported worse-than-expected Q2 revenue results and maintained FY23 revenue guidance.
- 12 Health Care Stocks Moving In Monday's Intraday Session
- Why Krystal Biotech Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Why Aceragen (ACGN) Stock Is Down 30% Today
- Aceragen shares are trading lower after the company announced it will delist from the Nasdaq.
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- Why Kosmos Energy Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
- 12 Health Care Stocks Moving In Friday's After-Market Session
- Aceragen, Inc. To Delist from The Nasdaq Stock Market
Latest ARGX
- SEC Form 6-K filed by argenx SE
- argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
- SEC Form 6-K filed by argenx SE
- argenx announces Annual General Meeting of Shareholders on May 6, 2026
- SEC Form 20-F filed by argenx SE
- SEC Form 6-K filed by argenx SE
- argenx upgraded by Deutsche Bank
- SEC Form 6-K filed by argenx SE
- argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
- SEC Form 6-K filed by argenx SE